Business
LivaNova to Highlight Real-World Evidence from CORE-VNS Study and New Health Economics Analyses at American Epilepsy Society 2025 Annual Meeting
Eight scientific posters demonstrate significant seizure reduction and improved outcomes with VNS Therapy in patients with Drug-Resistant Epilepsy
About this update from Livanova Plc
[{"type":"text","content":"\nEight scientific posters demonstrate significant seizure reduction and improved outcomes with VNS Therapy in patients with Drug-Resistant Epilepsy\n\n LONDON--(BUSINESS WIRE)--\n\nLivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present eight posters at the American Epilepsy Society (AES) Annual Meeting, taking place Dec. 5-9 in Atlanta. These presentations highlight real-world evidence from the CORE-VNS study, the largest prospective, multinational observational study of VNS Therapy™ for Drug-Resistant Epilepsy (DRE), and new health economics analyses.\n\n“At the heart of LivaNova’s purpose as a Company, we aim to help patients reclaim their lives by improving global access to epilepsy treatment and supporting better outcomes,” said Stephanie Bolton, LivaNova President, Global Epilepsy. “Our CORE-VNS study confirms the proven benefits of VNS Therapy in patients with Drug-Resistant Epilepsy and reveals there are benefits of use earlier in the treatment algorithm. We are focused on contributing to the science of the treatment of epilepsy, and these poster presentations will share details on seizure reduction over time and decreases in healthcare burden.”\n\nThe scientific poster presentations feature new research from leading independent investigators in collaboration with scientific experts from LivaNova. Conference attendees will have an opportunity to view posters from Dec. 6-8 (times vary). All posters will also be shown in the LivaNova Scientific Exhibit on Mon., Dec. 8, from 8-11 a.m. ET in Room B213/214 of the Georgia World Congress Center.\n\nAbstracts and posters will be available on the AES website during and following the congress.\n\n“We value the opportunity to share current evidence and deepen the understanding of VNS Therapy,\" said Kate Nichol, PhD, LivaNova Vice President, Medical Affairs. “The sheer size of the CORE-VNS study allows us to analyze subgroups and seizure types, providing a strong dataset for evidence-based decision making from clinicians.”\n\nSat., Dec. 6 (both from 12-2 p.m. ET)\n\n\nVNS Therapy is Associated with Reduced Severe Seizure Burden in Children Early in the Treatment (3 months) of DRE with Continued Improvement Over 36 Months (Poster 1.303) – Description: Children and adolescents showed early improvements at 3 months and sustained seizu...